In the BioHarmony Drug Report Database
Nexletol, Nilemdo (bempedoic acid) is a small molecule pharmaceutical. Bempedoic acid was first approved as Nexletol on 2020-02-21. It is used to treat atherosclerosis and hyperlipoproteinemia type II in the USA. It has been approved in Europe to treat dyslipidemias and hypercholesterolemia. The pharmaceutical is active against ATP-citrate synthase. Nexletol’s patents are valid until 2025-12-03 (FDA).
Image (chem structure or protein)